Filing Flows › Ultragenyx Pharmaceutical (RARE) › Guidance & outlook
Ultragenyx Pharmaceutical (RARE) guidance and outlook
Ultragenyx Pharmaceutical (RARE) reaffirmed its guidance on Nov 3, 2026: Revenue $730M–$760M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $730M–$760M | reaffirmed |
| Revenue | FY2026 | $500M–$520M | reaffirmed |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Ultragenyx Pharmaceutical's latest quarter
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Ultragenyx Pharmaceutical raise or lower its guidance?
Ultragenyx Pharmaceutical (RARE) reaffirmed its guidance on Nov 3, 2026: Revenue $730M–$760M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.